NATCO Pharma Increases Stake in Adcock Ingram to 49% With ₹1,060 Crore Acquisition

NATCO Pharma has completed the acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited, a leading pharmaceutical and healthcare company in South Africa.

Following the completion of the transaction, NATCO's shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was carried out through NATCO Pharma South Africa Proprietary Limited, the company's wholly owned subsidiary in South Africa.

The transaction was completed for an aggregate consideration of around ZAR 1.81 billion, which is approximately ₹1,060 crore based on the exchange rate applicable to the transaction.

A Key Step in NATCO's Africa Growth Strategy

The acquisition marks another important milestone in NATCO Pharma's long-term expansion plans in Africa.

The company first acquired a 35.75% stake in Adcock Ingram during the company's delisting process in 2025. The process began with the announcement of a firm intention offer in July 2025, followed by shareholder approval in October 2025, and the completion of the transaction in November 2025.

In July 2026, NATCO's Board approved the purchase of an additional 13.25% stake, and the transaction has now been completed after meeting all regulatory approvals and customary closing conditions.

About NATCO Pharma

Founded in 1981, NATCO Pharma is a publicly listed pharmaceutical company on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). The company has a market capitalisation of around US$1.82 billion.

NATCO is known for its focus on pharmaceutical research and development, particularly in specialised and high-value medicines. Its product portfolio includes therapies for oncology, cardiology, neurology and several other therapeutic areas.

Read More: Nifty Weekly Expiry Today: Kaynes Technology India Under F&O Ban on July 14, 2026

NATCO Pharma Share Price Movement

As of 2:06 PM on July 14, 2026, NATCO Pharma share price (NSE: NATCOPHARM ) was trading at ₹967.70 on the NSE, down ₹12.25 or 1.25% for the day. The stock opened at ₹978.90 and moved between an intraday low of ₹966.50 and a high of ₹983.50. 

Conclusion

By increasing its stake in Adcock Ingram to 49%, NATCO Pharma has strengthened its presence in the South African pharmaceutical market. The acquisition aligns with the company's long-term strategy to expand its international footprint and enhance its position in Africa, while continuing to grow its global pharmaceutical business. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.